title: [Ornithinimicrobium pekingense ocular infection].
authors: E
authors: E
authors: Borsali
authors: A
authors: A
authors: Le Bouter
authors: G
authors: G
authors: Abdiche
authors: P
authors: P
authors: Goldschmdt
authors: P
authors: P
authors: Legrand
authors: L
authors: L
authors: Batellier
authors: D
authors: D
authors: Gleize
authors: L
authors: L
authors: Laroche
authors: C
authors: C
authors: Chaumeil
mesh_terms: D000192:Actinomycetales / Q000187:drug effects / Q000302:isolation & purification* / Q000472:pathogenicity; D000193:Actinomycetales Infections / Q000188:drug therapy / Q000382:microbiology*; D000368:Aged; D002386:Cataract / Q000150:complications; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000627:therapeutic use; D015715:Corneal Edema / Q000209:etiology; D003320:Corneal Ulcer / Q000188:drug therapy / Q000382:microbiology*; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D005672:Fusidic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D015948:Keratoplasty, Penetrating; D009824:Ointments; D009883:Ophthalmic Solutions; D011183:Postoperative Complications / Q000188:drug therapy / Q000382:microbiology; D012294:Rifamycins / Q000008:administration & dosage / Q000627:therapeutic use; D014031:Tobramycin / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D009824:Ointments; D009883:Ophthalmic Solutions; D012294:Rifamycins; D005672:Fusidic Acid; D002939:Ciprofloxacin; C023808:rifamycin SV; D014031:Tobramycin